Agenus Inc. (NASDAQ:AGEN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Thursday.

AGEN has been the topic of several other research reports. Zacks Investment Research downgraded Agenus from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Friday, August 4th. Finally, BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $5.88.

Agenus (AGEN) traded up 2.97% on Thursday, hitting $4.16. 1,394,276 shares of the stock were exchanged. The company’s 50 day moving average price is $3.99 and its 200-day moving average price is $3.85. The company’s market cap is $414.80 million. Agenus has a one year low of $3.20 and a one year high of $7.49.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $6.66 million. During the same quarter last year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was down 36.1% compared to the same quarter last year. Equities research analysts predict that Agenus will post ($1.13) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Agenus Inc. (AGEN) Upgraded by ValuEngine to “Sell”” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/09/agenus-inc-agen-upgraded-by-valuengine-to-sell.html.

Institutional investors have recently made changes to their positions in the company. OxFORD Asset Management LLP acquired a new stake in shares of Agenus in the second quarter worth $141,000. SG Americas Securities LLC grew its stake in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 23,689 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 6,381 shares during the last quarter. American International Group Inc. grew its stake in shares of Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,984 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in shares of Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 34,833 shares during the last quarter. Institutional investors and hedge funds own 39.51% of the company’s stock.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.